Evaluating Treatment Options for Opioid Use Disorder: Insights from Overdose History

Category	Detail
Condition	Opioid Use Disorder (OUD)
Key Mechanisms	Opioid agonist therapy (OAT) with buprenorphine-naloxone or methadone reduces mortality and overdose risk.
Target Population	Individuals with opioid use disorder, particularly those with a history of nonfatal overdose.
Care Setting	Clinical settings providing opioid agonist therapy.

Methadone initiation after overdose is associated with a survival benefit compared to buprenorphine-naloxone.
Overdose and mortality rates are significantly lower with OAT than without.
Retention rates for methadone and buprenorphine-naloxone are low, averaging 25 and 16 days respectively.
Patient preferences should be prioritized in treatment choices to improve retention.
Research should focus on enhancing patient engagement in OAT rather than solely comparing medication efficacy.

Consider methadone as a first-line option for patients with OUD, especially after a nonfatal overdose.

Methadone may pose greater risks due to its adverse effect profile and programmatic requirements.

Individuals with opioid use disorder, particularly those with recent overdose history.

Buprenorphine-naloxone has been associated with lower overdose risk during treatment.

Provide low-threshold access to evidence-based treatment options.
Honor patient preferences in medication selection to enhance retention.
Investigate innovative approaches to support continued patient engagement in OAT care.

Clinical Scorecard: Evaluating Treatment Options for Opioid Use Disorder: Insights from Overdose History